Cancer Centers Working Group’s Report
On June 23, 2014, the National Cancer Advisory Board (NCAB) voted to accept a report prepared by its Cancer Centers Working Group (WG). In 2012, the WG was tasked to examine funding patterns and policies related to the Cancer Center Support Grant award levels and, if appropriate, to recommend changes and alternative approaches. NCI will now consider the WG’s recommendations and develop an implementation plan, which will be presented when the plan is available, and only after thorough discussion and coordination with interested partners. View the full report and its recommendations.
Participation in Trials of Rare Cancers
NCI-designated Cancer Centers play a key national role in developing new therapies in rare cancers. They are expected to lead, and/or participate in, NCI’s National Clinical Trials Network trials, including studies of rare cancers, cancers involving rare molecular subtypes, and uncommon clinical subsets of more common cancers. While Centers, through their Protocol Review and Monitoring System (PRMS), have the authority to close trials for poor accrual, exceptions should be made for trials involving rare diseases.
NCI–designated Cancer Center Logos
NCI–designated Cancer Centers and NCI–designated Comprehensive Cancer Centers
will be allowed to use the NCI Cancer Center logo, appropriate to their designation,
in the promotion, advocacy, educational, and other related activities of the
individual cancer center. Cancer Centers and Comprehensive Cancer Centers are not allowed to
use the NCI logo.
Click to see the
full policy.—posted 11/05/2013